Opinion

Video

Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Video content above is prompted by the following:

  1. What additional factors do you consider when determining the most effective sequence of these therapies (FTD/TPI plus bevacizumab, fruquintinib, regorafenib)?
  2. What future research is needed to better understand the optimal sequencing of these therapies?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Related Content
Man holding paper model of lungs | Image credit: Elena - stock.adobe.com
July 3rd 2025

Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control

Jared Kaltwasser
Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Hidradenitis suppurativa. | Image Credit: syahrir - stock.adobe.com
July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro
Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
UV Safety Awareness Month | Image Credit: Nass Studio - stock.adobe.com
July 1st 2025

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

Brooke McCormick
July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.
Outside of patient diversity, the researchers call for variety in data types to strengthen AI models, with a compilation of patient records with genomic data and images. | Image credit: natali_mis - stock.adobe.com
July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor
While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo